Skip to main content
. 2022 May 18;28(18):4003–4017. doi: 10.1158/1078-0432.CCR-21-3648

Figure 2.

Figure 2. Kaplan–Meier plot of overall survival in patients who received one (dotted lines) and one or more (solid lines) prior lines of therapy. A, Tafasitamab plus lenalidomide versus systemic therapies pooled. B, Tafasitamab plus lenalidomide versus BR. C, Tafasitamab plus lenalidomide versus R-GemOx. BR, bendamustine + rituximab; CI, confidence interval; HR, hazard ratio; KM; Kaplan–Meier; L, line; LEN; lenalidomide; NR, not reached; R-GemOx, rituximab + gemcitabine + oxaliplatin; Tafa, tafasitamab.

Kaplan–Meier plot of overall survival in patients who received one (dotted lines) and one or more (solid lines) prior lines of therapy. A, Tafasitamab plus lenalidomide versus systemic therapies pooled. B, Tafasitamab plus lenalidomide versus BR. C, Tafasitamab plus lenalidomide versus R-GemOx. BR, bendamustine + rituximab; CI, confidence interval; HR, hazard ratio; KM; Kaplan–Meier; L, line; LEN; lenalidomide; NR, not reached; R-GemOx, rituximab + gemcitabine + oxaliplatin; Tafa, tafasitamab.